News and Announcements

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

By Benjamin Chiou

Date: Thursday 14 Mar 2024

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.
Amolyt, which is a specialist in the treatment of rare endocrine disease, will be purchased for $800m upfront on completion of the...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page